{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:26:48Z","timestamp":1792175208764,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":127,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.03.054","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T11:18:03Z","timestamp":1680002283000},"page":"2879-2886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database"],"prefix":"10.1016","volume":"41","author":[{"given":"Greta","family":"Santi Laurini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Montanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bonaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Motola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.054_b0005","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020. February 8, 2022. (https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)."},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.054_b0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"27","key":"10.1016\/j.vaccine.2023.03.054_b0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.054_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"50","key":"10.1016\/j.vaccine.2023.03.054_b0025","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.03.054_b0030","unstructured":"Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. February 8, 2022. (https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/comirnaty-and-pfizer-biontech-covid-19-vaccine)."},{"issue":"19","key":"10.1016\/j.vaccine.2023.03.054_b0035","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1056\/NEJMp2031373","article-title":"Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations","volume":"383","author":"Krause","year":"2020","journal-title":"N Engl J Med"},{"issue":"5152","key":"10.1016\/j.vaccine.2023.03.054_b0040","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.03.054_b0045","unstructured":"Food and Drug Administration. Spikevax and Moderna COVID-19 Vaccine. February 8, 2022. (https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/spikevax-and-moderna-covid-19-vaccine)."},{"issue":"14","key":"10.1016\/j.vaccine.2023.03.054_b0050","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.03.054_b0055","unstructured":"Centers for Disease Control and Prevention. About The Vaccine Adverse Event Reporting System (VAERS). February 10, 2022. (https:\/\/wonder.cdc.gov\/controller\/datarequest\/D8;jsessionid=C2D605C8C4483B0B97F1BCDCAA8C)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0060","unstructured":"Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). February 10, 2022. (https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vaers\/index.html)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0065","unstructured":"Food and Drug Administration. CFR - Code of Federal Regulations Title 21. February 10, 2022. (https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0070","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. October 15, 2021. (https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0075","unstructured":"Food and Drug Administration. Emergency Use Authorization for Vaccines to Prevent COVID-19. February 28, 2022. (https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/emergency-use-authorization-vaccines-prevent-covid-19)."},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.054_b0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.054_b0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/vaccines10020233","article-title":"Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine","volume":"10","author":"Green","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.03.054_b0090","unstructured":"Food and Drug Administration. FDA Approves First COVID-19 Vaccine. February 25, 2022. (https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0095","unstructured":"European Medicine Agency. Comirnaty\u00ae Summary of Product Characteristics. March 3, 2022. (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0100","unstructured":"European Medicine Agency. Spikevax\u00ae Summary of Product Characteristics. March 3, 2022. (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)."},{"issue":"3","key":"10.1016\/j.vaccine.2023.03.054_b0105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/vaccines10030408","article-title":"A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System","volume":"10","author":"Gallo","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.03.054_b0110","unstructured":"Ministry of Health. Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including). March 5, 20(https:\/\/www.gov.il\/en\/departments\/news\/01062021-03)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0115","article-title":"Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?","volume":"373","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.03.054_b0120","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2023.03.054_b0125","unstructured":"Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA COVID-19 Vaccination. March 8, 2022. (https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/myocarditis.html)."},{"issue":"23","key":"10.1016\/j.vaccine.2023.03.054_b0130","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 Vaccination in a Large Health Care Organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2023.03.054_b0135","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.054_b0140","unstructured":"Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. March 8, 2022. (https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/05-COVID-Wallace-508.pdf)."},{"issue":"8","key":"10.1016\/j.vaccine.2023.03.054_b0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.054_b0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.03.054_b0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMra2035343","article-title":"Maintaining Safety with SARS-CoV-2 Vaccines","volume":"384","author":"Longo","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.054_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis","volume":"20","author":"Sobczak","year":"2022","journal-title":"Clin Mol Allergy"},{"issue":"25","key":"10.1016\/j.vaccine.2023.03.054_b0165","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.vaccine.2021.04.066","article-title":"Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines","volume":"39","author":"Somiya","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.054_b0170","unstructured":"Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. March 10, 2022. (https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0175","unstructured":"Centers for Disease Control and Prevention. Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. March 10, 2022. (https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/managing-anaphylaxis.html)."},{"issue":"9","key":"10.1016\/j.vaccine.2023.03.054_b0180","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2023.03.054_b0185","unstructured":"Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. March 14, 2022. (https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0190","unstructured":"World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). March 14, 2022. (https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-TTS-2021.1)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0195","unstructured":"See I. CDC Awardee COVID-19 Vaccination Planning Meeting. March 14, 2022. (https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-12-16\/02-COVID-See-508.pdf)."},{"key":"10.1016\/j.vaccine.2023.03.054_b0200","unstructured":"Vaccine Adverse Event Reporting System. VAERS Data. March 15, 2022. (https:\/\/vaers.hhs.gov\/data.html)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:52Z","timestamp":1759404292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23003481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23003481"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}